


PCT

DOCKET NO.: JJPR-0177/ORT-1509 PCT

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Steven W. Sutton and Timothy W.

Lovenberg

Application No.: 10/537,732

Filing Date: June 7, 2005

For: METHOD FOR IDENTIFYING MODULATORS OF HUMAN OREXIN-2
RECEPTOR

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

DATE OF DEPOSIT:

8/25/05

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: David M. De Santo

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:
 - Certification in Accordance with § 1.97(e) is attached; or
 - The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).
- Copies of reference numbers **1 thru 20** listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: August 22, 2005

Phillip A. Singer
Phillip A. Singer
Registration NO.: 40,176

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. JJPR-0177/ORT-1509PCT	Application No. 10/537,732
		Applicant Steven W. Sutton and Timothy W. Lovenberg	
		Filing Date June 7, 2005	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Chemelli, R.M. et al., "Narcolepsy in <i>orexin</i> Knockout Mice: Molecular Genetics of Sleep Regulation", <i>Cell</i> , 1999, 98, 437-451	
	2	Chen, Chiung-Tong et al., "Pressor Effects of Orexins Injected Intracisternally and to Rostral Ventrolateral Medulla of Anesthetized Rats", <i>Am. J. Physiol.</i> , 2000, 278, R692-R697	
	3	Cheng and Prusoff, "Relationship between the Inhibition Constant (k ₁) and the Concentration of Inhibitor which Causes 50 Per Cent Inhibition (i ₅₀) of an Enzymatic Reaction", <i>Biochemical Pharmacology</i> , 1973, 22, 3099-3108	
	4	Conklin, B.R. et al., "Substitution of Three Amino Acids Switches Receptor Specificity of G _q α to that of G _i α", <i>Nature</i> , 1993, 363, 274-276	
	5	Fults, D. et al., "Establishment and Characterization of a Human Primitive Neuroectodermal Tumor Cell Line from the Cerebral Hemisphere", <i>Journal of Neuropathology and Experimental of Neuropathologists</i> , 1992, 51(3), 272-280	
	6	Hara, J. et al., "Genetic Ablation of Orexin Neurons in Mice Results in Narcolepsy, Hypophagia, and Obesity", <i>Neuron</i> , 2001, 30, 345-354	
	7	Kirchgessner, A.L. et al., "Orexin Synthesis and Response in the Gut" <i>Neuron</i> , 1999, 24, 941-951	
	8	Lin, L. et al., "The Sleep Disorder Canine Narcolepsy is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene", <i>Cell</i> , 1999, 98, 365-376	
	9	Mignot, E. et al., "Complex HLA-DR and-DQ Interactions Confer Risk of Narcolepsy-Cataplexy in Three Ethnic Groups", <i>Am. J. Hum. Genet.</i> , 2001, 68, 686-699	
	10	Milligan, G. et al., "Chimaeric Gα Proteins" Their Potential Use in Drug Discovery", <i>Trends Pharmacol.</i> , 1999, 20, 118-124	
	11	Mignot, E. et al., "Narcolepsy and the HLA System", <i>New England Journal of Medicine</i> , 2001, 344, 692	
EXAMINER		DATE CONSIDERED	



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. JJPR-0177/ORT-1509PCT	Application No. 10/537,732
		Applicant Steven W. Sutton and Timothy W. Lovenberg	
		Filing Date June 7, 2005	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	12	Nakamura, T. et al., "Orexin-Induced Hyperlocomotion and Stereotypy are Mediated by the Dopaminergic System", <i>Brain Research</i> , 2000 , 873 181-187	
	13	Peyron, C. et al., "Neurons Containing Hypocretin (Orexin) project to Multiple Neuronal Systems", <i>The Journal of Neuroscience</i> , 1998 , 18(23), 9996-10015	
	14	Peyron, C. et al., "A Mutation in a Case of Early Onset Narcolepsy and a Generalized Absence of Hypocretin Peptides in Human Narcoleptic Brains" <i>Nature Medicine</i> , 2000 , 6, 991-997	
	15	Piper, D.C. et al., "The Novel Brain Neuropeptide, Orexin-A, Modulates the Sleep-Wake Cycle of Rats", <i>European Journal of Neuroscience</i> , 2000 , 12, 726-730	
	16	Samson, W.K. et al., "Cardiovascular Regulatory Actions of the Hypocretins in Brain" <i>Brain Research</i> , 1999 , 831, 248-253	
	17	Shirasaka, T. et al., "Sympathetic and Cardiovascular Actions of Orexins in Conscious Rats" <i>American J. Physiological Society</i> , 1999 , 277, R1780-R1785	
	18	Takahashi, N. et al., "Stimulation of Gastric Acid Secretion by Centrally Administered Orexin-A in Conscious Rats", <i>Biochemical and Biophysical Research Communications</i> , 1999 , 254, 623-627	
	19	van den Pol, A.N. "Hypothalamic Hypocretin (Orexin): Robust Innervation of the Spinal Cord", <i>The Journal of Neuroscience</i> , 1999 , 19, 3171-3182	
	20	Yamanaka, A. et al., "Orexins Activate Histaminergic Neurons via the Orexin 2 Receptor", <i>Biochemical and Biophysical Research Communications</i> , 2002 , 290, 1237-1245	
EXAMINER		DATE CONSIDERED	